GILD

130.50

0.15% -0.19

시장 영업 전: 131.00 0.50 +0.38%

길리어드 사이언스 (GILD)

개요 뉴스 가격 이력 옵션 체인 Financials GILD 왜 하락? 토론 예측 주식 분할 배당 이력

전일 마감가:

$130.69

열려 있는:

$130.015

하루 거래량:

4.92M

Relative Volume:

0.82

시가총액:

$162.02B

수익:

$29.79B

순이익/손실:

$9.22B

주가수익비율:

17.76

EPS:

7.3494

순현금흐름:

$10.23B

1주 성능:

-1.18%

1개월 성능:

-2.09%

6개월 성능:

+3.05%

1년 성능:

+21.15%

1일 변동 폭

$129.42

$131.34

1주일 범위

$128.34

$132.81

52주 변동 폭

$104.46

$157.29

길리어드 사이언스 Stock (GILD) Company Profile

명칭

Gilead Sciences Inc

부문

Healthcare (1106)

산업

Drug Manufacturers - General (20)

전화

(650) 574-3000

주소

333 LAKESIDE DR, FOSTER CITY, CA

직원

17,000

트위터

@GileadSciences

다음 수익 날짜

2026-05-07

최신 SEC 제출 서류

GILD's Discussions on Twitter

Compare GILD vs LLY, JNJ, ABBV, AZN, NVS

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
GILD Gilead Sciences Inc	130.50	162.26B	29.79B	9.22B	10.23B	7.3494
LLY Lilly Eli Co	1,041.65	908.57B	72.25B	25.28B	10.37B	27.78
JNJ Johnson Johnson	231.73	552.02B	96.36B	21.04B	17.80B	8.6488
ABBV Abbvie Inc	214.50	375.09B	62.82B	3.60B	19.98B	2.0274
AZN Astrazeneca Plc	189.75	290.72B	60.48B	10.40B	8.05B	3.3297
NVS Novartis Ag Adr	151.76	287.07B	54.66B	13.58B	16.05B	7.0171

길리어드 사이언스 Stock (GILD) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2026-03-10	개시	Jefferies	Buy
2026-02-20	개시	Barclays	Equal Weight
2026-02-11	재확인	Needham	Buy
2026-01-07	재개	UBS	Buy
2025-11-24	재개	Truist	Buy
2025-11-13	개시	Scotiabank	Sector Outperform
2025-08-19	업그레이드	Daiwa Securities	Neutral → Outperform
2025-08-08	업그레이드	Truist	Hold → Buy
2025-07-25	업그레이드	Needham	Hold → Buy
2025-04-22	재개	Cantor Fitzgerald	Overweight
2025-03-04	재확인	Oppenheimer	Outperform
2025-02-18	업그레이드	Deutsche Bank	Hold → Buy
2025-02-13	업그레이드	DZ Bank	Hold → Buy
2025-01-10	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2024-12-10	재개	BofA Securities	Buy
2024-11-15	개시	Wolfe Research	Outperform
2024-11-14	개시	Citigroup	Buy
2024-11-08	다운그레이드	Maxim Group	Buy → Hold
2024-10-21	업그레이드	Leerink Partners	Market Perform → Outperform
2024-10-17	개시	Bernstein	Outperform
2024-10-07	업그레이드	Wells Fargo	Equal Weight → Overweight
2024-07-08	업그레이드	Raymond James	Mkt Perform → Outperform
2024-05-01	재확인	Maxim Group	Buy
2024-04-24	업그레이드	HSBC Securities	Reduce → Hold
2024-02-22	다운그레이드	Truist	Buy → Hold
2023-11-09	개시	Deutsche Bank	Hold
2023-09-08	업그레이드	BofA Securities	Neutral → Buy
2023-09-06	개시	HSBC Securities	Reduce
2023-07-24	재확인	Barclays	Equal Weight
2023-05-16	업그레이드	BMO Capital Markets	Market Perform → Outperform
2023-04-28	재개	Piper Sandler	Overweight
2023-01-03	다운그레이드	RBC Capital Mkts	Outperform → Sector Perform
2022-12-13	재개	BofA Securities	Neutral
2022-12-09	다운그레이드	DZ Bank	Buy → Hold
2022-10-31	업그레이드	Barclays	Underweight → Equal Weight
2022-10-28	재확인	BMO Capital Markets	Market Perform
2022-10-28	재확인	Cowen	Outperform
2022-10-28	재확인	JP Morgan	Overweight
2022-10-28	재확인	Jefferies	Buy
2022-10-28	업그레이드	Piper Sandler	Neutral → Overweight
2022-10-28	재확인	RBC Capital Mkts	Outperform
2022-10-28	업그레이드	Truist	Hold → Buy
2022-10-28	재확인	Wells Fargo	Equal Weight
2022-10-04	업그레이드	JP Morgan	Neutral → Overweight
2022-07-13	개시	Cantor Fitzgerald	Neutral
2022-05-23	개시	SVB Leerink	Mkt Perform
2022-02-28	다운그레이드	BMO Capital Markets	Outperform → Market Perform
2022-02-02	재확인	BMO Capital Markets	Outperform
2022-02-02	재확인	BofA Securities	Neutral
2022-02-02	재확인	RBC Capital Mkts	Outperform
2022-02-02	재확인	Truist	Hold
2022-02-02	재확인	Wells Fargo	Equal Weight
2022-01-28	업그레이드	Argus	Hold → Buy
2022-01-06	다운그레이드	Morgan Stanley	Overweight → Equal-Weight
2021-12-09	재개	Wells Fargo	Equal Weight
2021-12-06	개시	Goldman	Neutral
2021-11-19	업그레이드	BMO Capital Markets	Market Perform → Outperform
2021-11-19	재개	Piper Sandler	Neutral
2021-10-20	재개	Cowen	Outperform
2021-07-30	재확인	BMO Capital Markets	Market Perform
2021-07-30	재확인	RBC Capital Mkts	Outperform
2021-04-01	업그레이드	Bernstein	Mkt Perform → Outperform
2021-03-30	업그레이드	Redburn	Neutral → Buy
2021-01-19	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2021-01-04	업그레이드	Guggenheim	Neutral → Buy
2020-11-03	재개	Morgan Stanley	Equal-Weight
2020-10-28	개시	UBS	Neutral
2020-09-30	재개	Jefferies	Buy
2020-09-15	업그레이드	Maxim Group	Hold → Buy
2020-07-31	재확인	Credit Suisse	Neutral
2020-07-31	재확인	Morgan Stanley	Equal-Weight
2020-07-31	재확인	Piper Sandler	Overweight
2020-07-31	재확인	RBC Capital Mkts	Outperform
2020-07-31	재확인	SunTrust	Hold
2020-07-31	재확인	Wells Fargo	Equal Weight
2020-07-20	업그레이드	Credit Suisse	Underperform → Neutral
2020-06-03	업그레이드	SVB Leerink	Mkt Perform → Outperform
2020-05-26	업그레이드	SunTrust	Sell → Hold
2020-05-01	다운그레이드	JP Morgan	Overweight → Neutral
2020-05-01	다운그레이드	Raymond James	Outperform → Mkt Perform
2020-05-01	다운그레이드	SunTrust	Hold → Sell
2020-04-27	다운그레이드	UBS	Buy → Neutral
2020-04-20	다운그레이드	BMO Capital Markets	Outperform → Market Perform
2020-04-20	다운그레이드	Wells Fargo	Overweight → Equal Weight
2020-04-17	다운그레이드	CFRA	Hold → Sell

모두보기

길리어드 사이언스 주식(GILD)의 최신 뉴스

06:16 AM

Zacks Research Forecasts Weaker Earnings for Gilead Sciences - MarketBeat

06:16 AM

05:43 AM

PNC Financial Services Group Inc. Has $58.19 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat

05:43 AM

05:21 AM

Northwestern Mutual Wealth Management Co. Buys 13,252 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

05:21 AM

03:15 AM

Key facts: Gilead buys Tubulis for $3.15B; remdesivir vs Bundibugyo - TradingView

03:15 AM

02:18 AM

New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology - BioSpace

02:18 AM

May 21, 2026

ETFs Investing in Gilead Sciences, Inc. Stocks - TradingView

May 21, 2026

Gilead Sciences, Inc. completed the acquisition of Tubulis GmbH from a group of shareholders. - marketscreener.com

May 21, 2026

Gilead Sciences, Inc. Revenue Breakdown – BVL:GILDUS - TradingView

May 21, 2026

Gilead Sciences (GILD) Is Among The Best Extremely Profitable Stocks To Buy According To Wall Street Analysts - Yahoo Finance

May 21, 2026

Gilead pledges 400K AmBisome doses to fight visceral leishmaniasis in expanded WHO collab - Fierce Pharma

May 21, 2026

Gilead Sciences Completes Acquisition of Tubulis - Contract Pharma

May 21, 2026

Why Gilead Sciences Is Now A Hold (Rating Upgrade) (NASDAQ:GILD) - Seeking Alpha

May 21, 2026

Gilead completes $3.15 billion acquisition of Tubulis By Investing.com - Investing.com Canada

May 21, 2026

Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio - Business Wire

May 21, 2026

Forget Moderna: This Biotech Juggernaut Is a Way Better Buy Right Now - 24/7 Wall St.

May 21, 2026

Gilead Renews WHO Partnership to Fight Deadly Kala-Azar - Contract Pharma

May 21, 2026

Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease - BioSpace

May 21, 2026

Leonteq Securities AG Takes Position in Gilead Sciences, Inc. $GILD - MarketBeat

May 21, 2026

Gilead Sciences extends WHO partnership to fight visceral leishmaniasis - StreetInsider

May 21, 2026

400,000 drug vials to fight a fatal parasite in 74% of VL hotspots - Stock Titan

May 21, 2026

Maxim Group upgrades Gilead Sciences (GILD) - MSN

May 21, 2026

May 20, 2026

Gilead Sciences (GILD) Announces Issuance of Senior Notes in New Indenture Agreement - GuruFocus

May 20, 2026

Gilead Sciences Launches New $3 Billion Senior Notes - TipRanks

May 20, 2026

Gilead Sciences issues $3 billion in senior notes across four tranches - StreetInsider

May 20, 2026

Gilead Sciences (GILD) prices multiple senior note series due 2028–2034 - Stock Titan

May 20, 2026

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance Singapore

May 20, 2026

Maxim Upgrades Gilead Sciences to Buy From Hold, Price Target Is $165 - Moomoo

May 20, 2026

Maxim Group Upgrades Gilead Sciences(GILD.US) to Buy Rating, Announces Target Price $165 - Moomoo

May 20, 2026

Morgan Stanley Reassesses Gilead Sciences (GILD) Outlook Following Quarterly Report - Yahoo Finance

May 20, 2026

Jag Capital Management LLC Buys New Stake in Gilead Sciences, Inc. $GILD - MarketBeat

May 20, 2026

Gilead Sciences, Inc. $GILD Shares Sold by Mitsubishi UFJ Asset Management UK Ltd. - MarketBeat

May 20, 2026

Fideuram Intesa Sanpaolo Private Banking S.P.A. Takes $50.80 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat

May 20, 2026

Gilead Sciences, Inc. $GILD Shares Sold by Banque Cantonale Vaudoise - MarketBeat

May 20, 2026

Atle Fund Management AB Sells 27,373 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

May 20, 2026

May 19, 2026

Yuhan expands API deals with Gilead, boosts South Korea productionCHOSUNBIZ - Chosunbiz

May 19, 2026

Yuhan Signs 210.2 Billion Won API Supply Deal with Gilead - Seoul Economic Daily

May 19, 2026

When Every Moment Matters: Kite’s CAR T-cell Therapy Helps Bring Hope to Patients - Gilead Sciences

May 19, 2026

Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases - GlobeNewswire Inc.

May 19, 2026

Argus Research Sticks to Its Buy Rating for Gilead Sciences (GILD) - The Globe and Mail

May 19, 2026

Gilead Sciences to buy clinical-stage biotech Tubulis for up to $5 billion - MSN

May 19, 2026

Gilead Sciences Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus

May 19, 2026

Daiwa Securities Group Issues Pessimistic Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - MarketBeat

May 19, 2026

Resona Asset Management Co. Ltd. Lowers Stake in Gilead Sciences, Inc. $GILD - MarketBeat

May 19, 2026

Profund Advisors LLC Buys 15,824 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

May 19, 2026

ProShare Advisors LLC Buys 623,752 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

May 19, 2026

Gilead Sciences (NASDAQ:GILD) Screens as a Top Dividend Stock with Strong Profitability and Health - ChartMill

May 19, 2026

Gilead Sciences Q1 2026 Earnings: Revenue Beat, Raised Guidance, and Key Analyst QuestionsNews and Statistics - IndexBox

May 19, 2026

Handelsbanken Fonder AB Sells 81,694 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

May 19, 2026